Gene expression profiling indicates that immunohistochemical expression of CD40 is a marker of an inflammatory reaction in the tumor stroma of diffuse large B-cell lymphoma

Leukemia and Lymphoma

Volumn 53, Issue 9, 2012, Pages 1764-1768

  Rydström, Karin ^a   Joost, Patrick ^a   Ehinger, Mats ^a   Edén, Patrik ^a   Jerkeman, Mats ^a   Cavallin Ståhl, Eva ^a   Linderoth, Johan ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

CD40; Diffuse large B cell lymphoma; gene expression profiling; tumor stroma

Indexed keywords

ALPHA5 INTEGRIN; ANTHRACYCLINE; BIGLYCAN; CD4 ANTIGEN; CD40 ANTIGEN; CD51 ANTIGEN; CD8 ANTIGEN; COLLAGEN; PROTEINASE; PROTEOGLYCAN;

ADULT; ANTIGEN PRESENTATION; ARTICLE; CANCER PROGNOSIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CELL INTERACTION; CONTROLLED STUDY; DNA MICROARRAY; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LARGE CELL LYMPHOMA; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

ANTIGENS, CD40; BIGLYCAN; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; COHORT STUDIES; FEMALE; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; INFLAMMATION; INTEGRIN ALPHAV; LYMPHOMA, LARGE B-CELL, DIFFUSE; MACROPHAGES; MALE; MIDDLE AGED; PROGNOSIS; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84864988511     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.666541     Document Type: Article

References (33)

1. Coiffi er B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diff use large-B-cell lymphoma. N Engl J Med 2002;346:235-242.
2. L inderoth J, Ehinger M, Jerkeman M, et a l. CD40 expression identifi es a prognostically favourable subgroup of diff use large B-cell lymphoma. Leuk Lymphoma 2007;48:1774-1779.
3. L inderoth J, Jerkeman M, Cavallin-Stahl E, et a l. Immunohistochemical expression of CD23 and CD40 may identify prognostically favorable subgroups of diff use large B-cell lymphoma: Immunohistochemical expression of CD23 and CD40 may identify prognostically favorable subgroups of diff use large B-cell lymphoma: Nordic Lymphoma Group Study Nordic Lymphoma Group Study. Clin Cancer Res 2003;9:722-728.
4. R ydstrom K, Linderoth J, Nyman H, et al. CD40 is a potential marker of favorable prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Leuk Lymphoma 2010;51:1643-1648.
5. H ans CP, Weisenburger DD, Greiner TC, et al. Confi rmation of the molecular classifi cation of diff use large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103: 275-282.
6. L inderoth J, Eden P, Ehinger M, et a l. Genes associated with the tumour microenvironment are differentially expressed in cured versus primary chemotherapy-refractory diff use large B-cell lymphoma. Br J Haematol 2008;141:423-432.
7. S aal LH, Troein C, Vallon-Christersson J, et al. BioArray Software Environment (BASE): A platform for comprehensive management and analysis of microarray data. Genome Biol 2002;3:software0003 - software0003.6.
8. Y ang YH, Dudoit S, Luu P, et al. Normalization for cDNA microarray data: A robust composite method addressing single and multiple slide systematic variation. Nucleic Acids Res 2002;30:e15.
9. A ndersson A, Eden P, Lindgren D, et a l. Gene expression profiling of leukemic cell lines reveals conserved molecular signatures among subtypes with specifi c genetic aberrations. Leukemia 2005;19: 1042-1050.
10. F ernebro J, Francis P, Eden P, et a l. Gene expression profi les relate to SS18/SSX fusion type in synovial sarcoma. Int J Cancer 2006; 118:1165-1172.
11. B enjamini Y, Hochberg Y. Controlling the false discovery rate: practical and powerful approach to multiple testing. J R Stat Soc 1995; 57:289-300.
12. v an Kooten C, Banchereau J. CD40-CD40 ligand. J Leukoc Biol 2000;67:2-17.
13. V estal RE, Wingett D, Knight K, et a l. Expression of CD40 in breast, colon, lung and ovarian tumors. Proc Am Assoc Cancer Res 1997;38:A1550.
14. B ennett SR, Carbone FR, Karamalis F, et al. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 1998;393:478-480.
15. Schultze JL, Cardoso AA, Freeman GJ, et a l. Follicular lymphomas can be induced to present alloantigen effi ciently: A conceptual model to improve their tumor immunogenicity. Proc Natl Acad Sci USA 1995;92:8200-8204.
16. French RR, Chan HT, Tutt AL, et a l. CD40 antibody evokes CD40 antibody evokes cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help. Nat Med 1999;5:548-553.
17. Luczynski W, Kowalczuk O, Ilendo E, et al. Upregulation of antigen-processing machinery components at mRNA level in acute lymphoblastic leukemia cells after CD40 stimulation. Ann Hematol 2007;86:339-345.
18. H oves S, Aigner M, Pfeiff er C, et al. In situ analysis of the antigenprocessing machinery in acute myeloid leukaemic blasts by tissue microarray. Leukemia 2009;23:877-885.
19. M ehta AM, Jordanova ES, Kenter GG, et al. Association of antigen processing machinery and HLA class I defects with clinicopathological outcome in cervical carcinoma. Cancer Immunol Immunother 2008; 57:197-206.
20. Iozzo RV, Schaefer L. Proteoglycans in health and disease: novel regulatory signaling mechanisms evoked by the small leucine-rich proteoglycans. FEBS J 2010;277:3864-3875.
21. Schaefer L, Babelova A, Kiss E, et al. Th e matrix component biglycan is proinfl ammatory and signals through Toll-like receptors 4 and 2 in macrophages. J Clin Invest 2005;115:2223-2233.
22. Lenz G, Wright G, Dave SS, et al. Stromal gene signatures in large- B-cell lymphomas. N Engl J Med 2008;359:2313-2323.
23. Evens AM, Sehn LH, Farinha P, et a l. Hypoxia-inducible factor-1 {alpha} expression predicts superior survival in patients with diff use large B-cell lymphoma treated with R-CHOP. J Clin Oncol 2010;28: 1017-1024.
24. Ansell SM, Stenson M, Habermann TM, et a l. Cd4 T-cell immune response to large B-cell non-Hodgkin's lymphoma predicts patient outcome. J Clin Oncol 2001;19:720-726.
25. I yengar P, Espina V, Williams TW, et a l. Adipocyte-derived collagen VI aff ects early mammary tumor progression in vivo, demonstrating a critical interaction in the tumor/stroma microenvironment. J Clin Invest 2005;115:1163-1176.
26. Lu JG, Sun YN, Wang C, et al. Role of the alpha v-integrin subunit in cell proliferation, apoptosis and tumor metastasis of laryngeal and hypopharyngeal squamous cell carcinomas: A clinical and in vitro investigation. Eur Arch Otorhinolaryngol 2009;266:89-96.
27. Galamb O, Sipos F, Spisak S, et a l. Potential biomarkers of colorectal adenoma-dysplasia-carcinoma progression: mRNA expression profi ling and in situ protein detection on TMAs reveal 15 sequentially upregulated and 2 downregulated genes. Cell Oncol 2009;31:19-29.
28. I shiwata T, Cho K, Kawahara K, et al. Role of lumican in cancer cells and adjacent stromal tissues in human pancreatic cancer. Oncol Rep 2007;18:537-543.
29. S eya T, Tanaka N, Shinji S, et a l. Lumican expression in advanced colorectal cancer with nodal metastasis correlates with poor prognosis. Oncol Rep 2006;16:1225-1230.
30. K odama J, Hasengaowa, Kusumoto T, et a l. Prognostic signifi cance of stromal versican expression in human endometrial cancer. Ann Oncol 2007;18:269-274.
31. L abropoulou VT, Th eocharis AD, Ravazoula P, et al. Versican but not decorin accumulation is related to metastatic potential and neovascularization in testicular germ cell tumours. Histopathology 2006;49:582-593.
32. Smith HW, Marshall CJ. Regulation of cell signalling by uPAR. Nat Rev Mol Cell Biol 2010;11:23-36.
33. R ojiani MV, Alidina J, Esposito N, et a l. Expression of MMP-2 correlates with increased angiogenesis in CNS metastasis of lung carcinoma. Int J Clin Exp Pathol 2010;3:775-781.